ReviewCurrent oncology reports2021

Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Robert Galvin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.